NKMAX CO., Ltd. announced that it expects to receive KRW 21.40019775 billion in funding
June 07, 2021
Share
NKMAX CO., Ltd. (KOSDAQ:A182400) announced a private placement of 512,835 convertible preferred shares at the price of KRW 13,650 per share for gross proceeds of KRW 7,000,197,750 and round 12 unregistered coupon nonguaranteed private convertible bonds for gross proceeds of KRW 14,400,000,000 for aggregate gross proceeds of KRW 21,400,197,750 on June 8, 2021. The preferred shares transaction will include participation from Fund 1 for 73,261 shares, Fund 2 for 73,261 shares, Fund 3 for 146,521 shares, Fund 4 for 73,261 shares, Fund 5 for 73,261 shares; managed by Asset One Asset Management, Fund 6 for 3,664 shares, Fund 7 for 7,327 shares, Fund 8 for 7,327 shares, Fund 9 for 14,653 shares, Fund 10 for 7,327 shares, Fund 11 for 7,327 shares, Fund 12 for 3,664 shares, Fund 13 for 7,327 shares, Fund 14 for 7,327 shares, Fund 15 for 7,327 shares; managed by Tiger Asset Management Discretionary Investment Co., Ltd. The convertible bonds are convertible into 1,024,327 common shares. The company will issue preferred shares of par value of KRW 500 per share through third party allocation method. The preferred shares will be locked up for a period of one year. The transaction has been approved by board of directors of the company. The payment date for the preferred shares transaction is June 25, 2021 and the convertible bonds transaction is on June 10, 2021.
NKMAX Co., Ltd., formerly ATGen, is a Korea-based company principally engaged in the research, development, manufacturing and supply of biological products. The Company is involved in the production and sale of recombinant proteins, monoclonal antibodies, NK cell activity test kits, cell therapy products, and in the provision of other related services. The NK cell activity test kits are provided under the name of NK Vue. The Company distributes its products within domestic market and to overseas markets.
NKMAX CO., LTD. 